Mutations( Hover over each mutational type to highlight genes covered )
AKT1
ALK
BRAF
CTNNB1
DDR2
EGFR
ERBB2
ESR1
FGFR1
FGFR2
FGFR3
FGFR4
HRAS
IDH1
IDH2
KEAP1
KIT
KRAS
MAP2K1
MET
NFE2L2
NRAS
NTRK1
NTRK2
NTRK3
PDGFRA
PIK3CA
POLE
PTEN
RB1
RET
ROS1
STK11
TP53
CDK4
DPYD
MYC
NKX2-1
NRG1
UGT1A1
Target 40 clinically actionable genes plus MSI
Detection of SNV, Indel, fusion, CNV and MSI
Fast turnaround time within
3 days
Automatic and secure data analysis
Specifications
Publications
1. Minghao Wang, Hongtao Xu, Qiang Han & Liang Wang (2023) Significance of YAP1–MAML2 rearrangement and GTF2I mutation in the diagnosis and differential diagnosis of metaplastic thymoma, Annals of Medicine, 55:2.
2. Lu, S., Pan, H., Wu, L. et al. Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial. Sig Transduct Target Ther 8, 249 (2023).